Replies to post #742869 on NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Enlighten me what is the unique immune environment in the brain. Is it harder for t-cells to reach?

As a matter of fact, when Dr. Liau first did the research on treating GBM with DC vaccine, the mainstream of academia were not for the idea and they said that brain was immune privileged and t-cells cannot reach tumors in brain. They were wrong, weren't they?

[flipper44]

DCVax-l will be covered, assuming approval, by an exclusive use marketing license for a decade from approval.

Beyond GBM, NWBO would pursue indications with their

1. Combination patent, which protects them out to 2036.

2. Hyperactive patent application, which if granted, (highly likely imo), protects them out to 2040 and is used to enhance Direct and DCVax-l.

3. Direct optimal patent, which goes out to 2036.